The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi: 10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi: 10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Cosby R, Bahl M, et al. Adjuvant chemotherapy and radiotherapy in resected pancreatic ductal adenocarcinoma: a systematic review and clinical practice guideline. Curr Oncol. 2023;30(7):6575–6586. doi: 10.3390/curroncol30070482
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Benson AB, et al. Pancreatic adenocarcinoma, version 1. NCCN Clin Pract Guidelines Oncol. 2024. [cited 2023 Dec 13]. Available form. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455
   Google Scholar
• Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol. 2019;26(5):1528–1534. doi: 10.1245/s10434-019-07309-8
   PubMed Web of Science ®Google Scholar
• Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–222. doi: 10.1097/SLA.0000000000002705
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III preopanc trial. J Clin Oncol. 2020;38(16):1763–1773. doi: 10.1200/JCO.19.02274
   PubMed Web of Science ®Google Scholar
• Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: what is the best protocol? Ann Gastroenterol Surg. 2020;4(2):100–108. doi: 10.1002/ags3.12311
   PubMed Web of Science ®Google Scholar
• Van Roessel S, Van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant Folfirinox treatment. JAMA Oncol. 2020;6(11):1733–1740. doi: 10.1001/jamaoncol.2020.3537
   PubMed Web of Science ®Google Scholar
• Sugawara T, Franco SR, Sherman S, et al. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol. 2023;9(3):316–323. doi: 10.1001/jamaoncol.2022.5808
   PubMed Web of Science ®Google Scholar
• Lee SH, Hwang DW, Yoo C, et al. Survival benefit of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant Folfirinox. Cancer Res Treat. 2023;55(3):956–968. doi: 10.4143/crt.2022.409
   PubMed Web of Science ®Google Scholar
• Perri G, Prakash L, Qiao W, et al. Postoperative chemotherapy benefits patients who received preoperative therapy and pancreatectomy for pancreatic adenocarcinoma. Ann Surg. 2020;271(6):996–1002. doi: 10.1097/SLA.0000000000003763
   PubMed Web of Science ®Google Scholar
• Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242–1258. doi: 10.1002/sim.5984
   PubMed Web of Science ®Google Scholar
• Oba A, Wu YHA, Colborn KL, et al. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: national cancer database cohort analysis. Br J Surg. 2022;109(5):450–454. doi: 10.1093/bjs/znac002
   PubMed Web of Science ®Google Scholar
• Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263–1270. doi: 10.1001/jamaoncol.2022.2319
   PubMed Web of Science ®Google Scholar
• Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450–4456. doi: 10.1200/JCO.2010.30.3446
   PubMed Web of Science ®Google Scholar
• Wang D, Liu C, Zhou Y, et al. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Radiat Oncol. 2020;15(1):107. doi: 10.1186/s13014-020-01561-z
   PubMed Web of Science ®Google Scholar
• Shimmura H, Kuramochi H, Jibiki N, et al. Dramatic response of Folfirinox regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. Jpn J Clin Oncol. 2019;49(11):1049–1054. doi: 10.1093/jjco/hyz141
   PubMed Web of Science ®Google Scholar
• Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24(8):2397–2403. doi: 10.1245/s10434-017-5885-4
   PubMed Web of Science ®Google Scholar
• Bauer K, Henne-Bruns D, Manzini G. Analysis of the CONKO-001 trial: is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer? Int J Risk Saf Med. 2023;34(1):29–40. doi: 10.3233/JRS-210015
   PubMed Web of Science ®Google Scholar
• Sinn M, Striefler JK, Sinn BV, et al. Does long-term survival in patients with pancreatic cancer really exist?-Results from the CONKO-001 study. J Surg Oncol. 2013;108(6):398–402.
   PubMed Web of Science ®Google Scholar
• Motoi F, Unno M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Jpn J Clin Oncol. 2020;50(5):483–489. doi: 10.1093/jjco/hyaa018
   PubMed Web of Science ®Google Scholar
• Chawla A, Ferrone CR. Neoadjuvant therapy for resectable pancreatic cancer: an evolving paradigm shift. Front Oncol. 2019;9:1085. doi: 10.3389/fonc.2019.01085
   PubMed Web of Science ®Google Scholar
• Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8(9):972–1017. doi: 10.6004/jnccn.2010.0073
   PubMed Web of Science ®Google Scholar
• McClaine RJ, Lowy AM, Sussman JJ, et al. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2010;12(1):73–79. doi: 10.1111/j.1477-2574.2009.00136.x
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Buschenfelde CMZ, et al. Preoperative/Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLOS Med. 2010;7(4):e1000267. doi: 10.1371/journal.pmed.1000267
   PubMed Web of Science ®Google Scholar
• Hammad AY, Hodges JC, AlMasri S, et al. Evaluation of adjuvant chemotherapy survival outcomes among patients with surgically resected pancreatic carcinoma with node-negative disease after neoadjuvant therapy. JAMA Surg. 2023;158(1):55–62. doi: 10.1001/jamasurg.2022.5696
   PubMed Web of Science ®Google Scholar
• Lo W, Zureikat A. Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials. Curr Opin Gastroenterol. 2022;38(5):521–531. doi: 10.1097/MOG.0000000000000874
   PubMed Web of Science ®Google Scholar
• Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802–1812. doi: 10.1007/s11605-015-2890-4
   PubMed Web of Science ®Google Scholar
• Suzuki T, Mori S, Shimizu T, et al. Clinical significance of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma. In Vivo. 2019;33(6):2027–2035. doi: 10.21873/invivo.11700
   PubMed Web of Science ®Google Scholar
• Ghanem I, Lora D, Herradon N, et al. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open. 2022;7(3):100485. doi: 10.1016/j.esmoop.2022.100485
   PubMed Web of Science ®Google Scholar
• Hu H, Xu Y, Zhang Q, et al. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on different AJCC 8th TNM stages: a propensity score matching analysis based on SEER database. PREPRINT (Version 1) available at Research Square. 2023 Nov 13. doi: 10.21203/rs.3.rs-3585676/v1
   Google Scholar